BIO logo

BIO

Bio-Rad Laboratories Inc. Class A

$277.50
-$3.65(-1.30%)
66
Overall
70
Value
72
Tech
57
Quality
How is this score calculated?
Market Cap
$7.50B
Volume
293.76K
52W Range
$211.43 - $343.12
Target Price
$327.50

Company Overview

Mkt Cap$7.50BPrice$277.50
Volume293.76KChange-1.30%
P/E Ratio-4.1Open$278.54
Revenue$2.6BPrev Close$281.15
Net Income$-1.8B52W Range$211.43 - $343.12
Div YieldN/ATarget$327.50
Overall66Value70
Quality57Technical72

No chart data available

About Bio-Rad Laboratories Inc. Class A

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Sector: Healthcare
Industry: Diagnostics & Research

Latest News

Analysts’ Opinions Are Mixed on These Healthcare Stocks: DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)....

Christine Brown17 hours ago

Ibio (IBIO) Receives a Buy from Chardan Capital

TipRanks Auto-Generated Intelligence Newsdeska day ago

iBio Advances to Clinical Stage With IBIO-600 Trial

TipRanks Auto-Generated Newsdeska day ago

Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)

TipRanks Auto-Generated Intelligence Newsdesk2 days ago

BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances

TipRanks Switzerland Auto-Generated Newsdesk3 days ago
ABCD
1SymbolPriceChangeVol
2BIO$277.50-1.3%293.76K
3
4
5
6

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.